Gilead Sciences (GILD) Upgraded to Strong-Buy at ValuEngine

Gilead Sciences (NASDAQ:GILD) was upgraded by stock analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

GILD has been the topic of several other reports. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Finally, Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective on the stock in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $86.56.

Gilead Sciences (NASDAQ GILD) traded up $1.10 during mid-day trading on Thursday, reaching $79.32. The company’s stock had a trading volume of 12,694,368 shares, compared to its average volume of 9,910,000. The company has a quick ratio of 3.56, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $89.54. The stock has a market cap of $103,590.00, a P/E ratio of 22.79, a PEG ratio of -1.75 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the previous year, the business earned $2.70 EPS. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences will post 6.41 EPS for the current fiscal year.

In related news, Chairman John C. Martin sold 50,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the transaction, the chairman now directly owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.51, for a total value of $2,087,750.00. Following the transaction, the executive vice president now owns 62,738 shares of the company’s stock, valued at $5,239,250.38. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 578,333 shares of company stock valued at $44,100,508. 1.30% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the business. Keel Point LLC boosted its position in Gilead Sciences by 0.4% during the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 12 shares during the period. Paradigm Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC lifted its holdings in shares of Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 41 shares during the period. Auxier Asset Management lifted its holdings in shares of Gilead Sciences by 1.4% in the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after buying an additional 96 shares during the period. Finally, Edmonds Duncan Registered Investment Advisors LLC lifted its holdings in shares of Gilead Sciences by 1.6% in the second quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 100 shares during the period. Institutional investors own 75.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences (GILD) Upgraded to Strong-Buy at ValuEngine” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/11/gilead-sciences-gild-upgraded-to-strong-buy-at-valuengine.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply